GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Tuesday, April 25, 2017

Teva for deficiencies related to an active pharmaceutical ingredient (API) manufacturing site in Hangzhou, China.

The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent 10 April to Teva for deficiencies related to an active pharmaceutical ingredient (API) manufacturing site in Hangzhou, China.

The letter, first disclosed in an SEC filing in which the company said it would respond by 1 May, includes two observations for failing to establish written procedures to monitor the progress and control the performance of processing steps that may cause variability in the quality characteristics of API, and for failing to establish a sampling plan based on scientifically sound sampling practices.
FDA investigators said the inspection from last September found that about 10% of certain API batches produced at the site over a two-year period failed to meet an impurity limit. An additional 10% of batches also yielded out-of-trend results. 
“You have reprocessed rejected out-of-specification (OOS) batches but failed to implement effective corrective and preventive actions (CAPA) to correct process design and control flaws that lead to excessive formation of this impurity during processing,” FDA said.
The agency also found Teva’s response to questions was “inadequate because it did not include the risk assessment and related scientific rationale to ensure that controls implemented for all batches will detect upstream processing variation and ensure final API quality.” 
FDA is seeking information on how Teva will improve batch sampling of some APIs to ensure that intra- and inter-batch variability during commercial manufacturing is detected; how the company evaluates other APIs for adequacy of sampling plans; and how it provides overall quality system improvements to ensure all sampling performed is representative and able to detect non-uniformity of the quality attributes that may vary within a batch. 
FDA also seeks an updated investigation into the root cause(s) of some OOS results and an improved CAPA plan, an explanation of Teva’s systems for incorporating reprocessing activities into Drug Master Files and more insight into the procedures that ensure reprocessed lots and process performance qualification lots are included in the site’s stability program.

Sourece: FDA , RAPS
GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences sharing.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news. Please ensure the guideline as per Regulatory agencies.


Post a Comment

Related Posts Plugin for WordPress, Blogger...


Popular Posts


Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner



Subscribe via email for free


Enter your email address:

Delivered by FeedBurner

Contact Form


Email *

Message *

Menu :
Powered by Blogger.



    Related Posts Plugin for WordPress, Blogger...


    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)


    Theme Support